Based on our finding of the low incidence of MSH6 mutations in HNPCC-suspected CRC patients and the percentage of non-MSI-high tumours in MSH6 mutation carriers from the literature, the probability of missing a mutation by not performing mutation analyses in patients with non-MSI-high CRCs is expected to be extremely low. This evidence concerns the gene MSH6 and neoplasm.